For 1994, IG Laboratories of the USA announced a loss of $3.6 million, down from $7.6 million a year earlier, excluding charges for restructuring and the write-off of impaired goodwill in 1993. Revenues for the year were $43.6 million, up 5%.
In the fourth quarter, revenues were $10 million, marginally lower than a year earlier. The loss for the quarter was $1.4 million, compared to $3.5 million in the like, year-earlier quarter. The cost reduction and improved efficiency measures that were taken in 1994 will continue through 1995, according to Elliot Hillback, president and chief executive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze